Profile data is unavailable for this security.
About the company
Guobang Pharma Ltd is a China-based company mainly engaged in the research and development, production, and sales of related products in the field of medicine and animal health products. The Company's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.
- Revenue in CNY (TTM)5.71bn
- Net income in CNY702.28m
- Incorporated1996
- Employees4.23k
- LocationGuobang Pharma Ltd#60 Xingmei RoadMeizhu Town, Xincang CountySHAOXING 312500ChinaCHN
- Phone+86 57 181396120
- Fax+86 57 181396129
- Websitehttp://www.gbgcn.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chongqing Genrix Biophrmctcl Co Ltd | 13.56m | -779.42m | 10.60bn | 547.00 | -- | 4.51 | -- | 782.02 | -2.13 | -2.13 | 0.037 | 6.42 | 0.0039 | 0.1009 | 1.37 | 24,790.27 | -22.22 | -- | -23.06 | -- | 55.87 | -- | -5,747.82 | -- | 18.62 | -- | 0.2454 | -- | 154.92 | -- | -39.03 | -- | -- | -- |
| Jiangsu Sinopep Allsin Bphrmctcl Co Ltd | 1.58bn | 421.47m | 10.67bn | 1.55k | 25.76 | 4.08 | -- | 6.77 | 1.88 | 1.88 | 7.14 | 11.91 | 0.4286 | 1.19 | 3.67 | 1,020,281.00 | 11.58 | 5.86 | 16.99 | 7.59 | 67.12 | 55.41 | 27.01 | 17.20 | 0.912 | 24.02 | 0.3477 | 27.59 | 58.69 | 32.24 | 26.20 | 29.99 | 27.32 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 2.58bn | 114.60m | 10.70bn | 2.55k | 95.17 | 1.38 | -- | 4.14 | 0.1194 | 0.1194 | 2.74 | 8.24 | 0.2118 | 1.48 | 0.7645 | 1,014,704.00 | 0.8822 | 3.48 | 1.17 | 4.78 | 34.52 | 38.93 | 4.17 | 10.08 | 2.23 | -- | 0.2888 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
| Mayinglong Pharmaceutical Group Co Ltd | 3.48bn | 482.37m | 10.82bn | 2.88k | 22.44 | 2.71 | -- | 3.11 | 1.12 | 1.12 | 8.08 | 9.28 | 0.6872 | 6.42 | 8.53 | 1,208,299.00 | 9.74 | 10.82 | 11.64 | 13.47 | 44.84 | 41.18 | 14.17 | 14.08 | 4.40 | -- | 0.0936 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
| Changchun BCHT Biotechnology Co | 1.61bn | 414.29m | 10.91bn | 1.24k | 26.34 | 2.60 | -- | 6.79 | 1.00 | 1.00 | 3.88 | 10.15 | 0.3181 | 1.00 | 1.06 | 1,295,333.00 | 8.20 | 9.95 | 10.23 | 12.81 | 87.55 | 86.63 | 25.77 | 24.03 | 1.85 | -- | 0.0147 | 10.55 | 70.30 | 12.36 | 175.98 | 31.37 | 21.04 | -- |
| Guobang Pharma Ltd | 5.71bn | 702.28m | 10.92bn | 4.23k | 15.50 | 1.39 | -- | 1.91 | 1.26 | 1.26 | 10.26 | 14.03 | 0.5599 | 3.29 | 7.84 | 1,350,536.00 | 6.87 | 10.36 | 8.88 | 14.24 | 23.87 | 27.49 | 12.27 | 15.01 | 1.70 | -- | 0.1992 | 18.24 | -6.49 | 10.28 | -33.49 | 23.77 | 35.60 | -- |
| Liaoning Chengda Biotechnology Co Ltd | 1.72bn | 332.10m | 11.36bn | 1.73k | 33.96 | 1.19 | -- | 6.61 | 0.8032 | 0.8032 | 4.16 | 22.93 | 0.1702 | 0.763 | 1.43 | 991,973.80 | 3.29 | 10.63 | 3.41 | 11.01 | 80.53 | 85.74 | 19.33 | 39.56 | 17.44 | -- | 0.0018 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
| KPC Pharmaceuticals Inc | 7.55bn | 446.07m | 11.51bn | 5.05k | 25.66 | 2.08 | -- | 1.52 | 0.5924 | 0.5924 | 10.03 | 7.31 | 0.7819 | 2.75 | 2.56 | 1,494,697.00 | 4.64 | 5.42 | 7.75 | 9.13 | 40.84 | 43.68 | 5.94 | 5.70 | 1.51 | -- | 0.172 | 35.75 | -6.99 | 1.64 | 16.05 | 5.79 | -21.33 | 14.87 |
Data as of Nov 01 2024. Currency figures normalised to Guobang Pharma Ltd's reporting currency: Chinese Yuan Renminbi CNY
5.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 6.32m | 2.10% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 2.70m | 0.90% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.43m | 0.47% |
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 1.31m | 0.43% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 30 Jun 2024 | 1.20m | 0.40% |
| Da Cheng Fund Management Co., Ltd.as of 30 Jun 2024 | 762.00k | 0.25% |
| Cinda Fund Management Co. Ltd.as of 30 Jun 2024 | 728.60k | 0.24% |
| China Asset Management Co., Ltd.as of 30 Jun 2024 | 576.20k | 0.19% |
| Chang Xin Asset Management Co., Ltd.as of 30 Jun 2024 | 542.40k | 0.18% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 475.80k | 0.16% |
More ▼
Data from 30 Jun 2024 - 27 Sep 2024Source: FactSet Research Systems Inc.
